

Name of the Issuer:		Medicamen Organics Limited	Last updated on	13th October, 2026
1	Type of Issue (IPO / FPO)		IPO	
2	Issue Size (Rs. Cr)* - Fresh Issue Size (Rs. Crores) *Source: Prospectus dated June 26 ,2024 and Final Post issue report July 10, 2024		10.54	
3	Grade of issue along with name of the rating agency Name Grade		Not Applicable Not Applicable	
4	Subscription Level (Number of times) Source: Final Post issue report dated July 01, 2024 *The above figure is after technical rejections		685.35*	
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges			
Particulars		%		
(i) allotment in the issue ⁽¹⁾		49.86%		
(ii) at the end of 1st Quarter immediately after the listing ⁽²⁾		5.47%		
(iii) at the end of 1st FY (March 31, 2025) ⁽²⁾		3.89%		
(iv) at the end of 2nd FY (March 31, 2026)*		Not available		
(v) at the end of 3rd FY (March 31, 2027)*		Not available		
*QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.				
(1) Source: Basis of Allotment				
(2) Source: Shareholding pattern as available on NSE				
6	Financials of the issuer (Consolidated)			
		(In Rs. Crore)		
Parameters	1st FY (March 31, 2025) ⁽¹⁾	2nd FY (March 31, 2026)	3rd FY (March 31, 2027)	
Income from operations	37.08	22.63	Not Applicable	
Net Profit for the period	3.27	-4.02	Not Applicable	
Paid-up equity share capital	11.7	12.166	Not Applicable	
Reserves excluding revaluation reserves	17.27	16.561	Not Applicable	
*Financials not disclosed as reporting for the relevant fiscal year has not been completed.				
(1) Source: Annual Report of the Company for relevant FY.				
7	Trading Status in the scrip of the issuer			
Company's Equity Shares are listed on NSE Limited (EMERGE Platform) The Shares have not been suspended or delisted.				
Particulars		Status		
(i) at the end of 1st FY (March 31, 2025)		Frequently Traded		
(ii) at the end of 2nd FY (March 31, 2026)*		Frequently Traded		
(iii) at the end of 3rd FY (March 31, 2027)*		Not Applicable		
*Trading status not disclosed as the relevant fiscal year has not been completed.				
8	Change in Directors of issuer from the disclosures in the offer document			
Particulars		Name of the Director	Appointed / Resigned	
(i) at the end of 1st FY (March 31, 2025)		Mr Shailesh Harimohan Gaur	Demise	
		Mr. Brijesh Kumar Chaubey	Appointment	
(ii) at the end of 2nd FY (March 31, 2026)*		Mr. Pankaj Tiwari	Appointment	
		Mr. Ashutosh Gupta	Re- appointment	
(iii) at the end of 3rd FY (March 31, 2027)*		Not Available	Not Available	
Source: Stock Exchange Filings				
* Changes in Directors of Issuer not updated as the relevant financial years have not been completed				

9 Status of implementation of project/ commencement of commercial production*

- (i) as disclosed in the offer document Not applicable
(ii) Actual implementation Not applicable
(iii) Reasons for delay in implementation, if any Not applicable

* The Company has not uploaded statement of deviation and utilization of funds report yet

10 Status of utilization of issue proceeds

- (i) as disclosed in the offer document

(Rs. crore)

Objects of the Fresh Issue	Amount
To meet Capital Expenditure requirements	4.00
Plant Updation and increase in production capacity	2.25
Funding of expenses proposed to be incurred towards Product registration in the international markets	3.00
General Corporate Purpose	0.39
Issue related expense	0.90
Total	10.54

Source: Prospectus dated June 26, 2024

- (ii) Actual utilization

(Rs. Lakhs)

Objects of the Fresh Issue	Amount
To meet Working Capital requirements	5.62
Plant Updation and increase in production capacity	2.25
Funding of expenses proposed to be incurred towards Product registration in the international markets	1.38
General Corporate Purpose	0.39
Issue related expense	0.90
Total	10.54

Source: * The Company is yet to file statement of deviation and utilization of funds on the stock exchange

- (iii) Reasons for deviation, if any Not applicable

11 Comments of monitoring agency

(a) Comments on use of funds	
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	Not Applicable, since Issue size is less than Rs. 50 crores
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data

Issue Price (Rs.):	34
Designated Stock Exchange:	NSE
Listing Date:	28-Jun-24

Price parameters	At close of listing day (June 28, 2024)	At close of 30th calendar day from listing day (July 28, 2024)	At close of 90th calendar day from listing day (September 26, 2024) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2025) ⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	144.70	83.40	65.00	21.70	159.40	19.60
NIFTY50*	24,010.60	24,836.10	26,216.05	23,585.03	25,989.42	22,140.81
NIFTY PHARMA	19,731.55	21,674.95	23,250.90	21,417.37	23,462.65	18,560.90

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2026)			As at the end of 3rd FY after the listing of the issue (March 31, 2027)		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	21.10	49.70	20.05	Not Available	Not Available	Not Available
NIFTY50*	22,679.40	26,373.20	21,743.65	Not Available	Not Available	Not Available
NIFTY PHARMA	22,011.60	23,540.90	19,121.10	Not Available	Not Available	Not Available

*Being index of NSE, the designated stock exchange

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

- (2) 90th calendar day shall be taken as listing date plus 89 calendar days.
(3) High and Low based on intra day prices
(4) In case of any reporting day falling on a holiday, previous trading day prices has been disclosed.

13 Basis for Issue Price

Accounting ratio	Name of the Company	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2025)	At the end of 2nd FY (March 31, 2026)**	At the end of 3rd FY (March 31, 2027)**
EPS	Issuer:	3.18	3.67	-3.41	Not Applicable
	Peer Group	Not Applicable	Not Applicable	Not Available	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Available	Not Applicable
Price to Earnings Ratio (P/E)	Issuer:	10.70	5.91	Not Available	Not Applicable
	Peer Group	Not Applicable	Not Applicable	Not Available	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Available	Not Applicable
RoNW(%)	Issuer:	0.16	13.78%	-13.70%	Not Applicable
	Peer Group	Not Applicable	Not Applicable	Not Available	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Available	Not Applicable
NAV	Issuer:	17.66	25.11	24.59	Not Applicable
	Peer Group	Not Applicable	Not Applicable	Not Available	Not Applicable
	Industry Avg:	Not Applicable	Not Applicable	Not Available	Not Applicable

Notes:

(1) Sourced from Prospectus dated June 26, 2024.

* The relevant data is not available yet.

**Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

(i) Earnings per Equity Share are computed in accordance with Accounting Standard 20 "earnings per Share" notified by the Companies (Accounting Standards) Rules, 2006.

(ii) NAV per share - Net asset value per Equity Share represents net worth as at the end of the Fiscal divided by the number of Equity Shares outstanding at the end of the Fiscal

(iii) P/E - Closing Market Price as of relevant fiscal year end / Basic EPS for the Fiscal

(iv) RoNW - Return on net worth (%) is net profit attributable to equity shareholders divided by net worth for the Fiscal

(v) The company believes that there are no listed Companies in India which are focused exclusively on the segment in which they operate.

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
26-Aug-24	Considered and approved the acquisition to effectively hold 51% (on a fully diluted basis) of Depot Pharmacy Yego Ltd Rwanda for an aggregate consideration of US\$75,000
27-Sep-24	Re-appointment of M/s. N C RAJ AND ASSOCIATES, Chartered Accountants (FRN: 002249N) Delhi, as the Statutory Auditors of the Company for a period of five
08-Oct-24	Medicamen Organics Limited has acquired a 51% stake in Depot Pharmacy Yego Ltd
21-Oct-24	Company informed demise of Mr. Shailesh Harimohan Gaur (DIN: 08673822), Executive Director
28-Nov-24	Appointment of Mr. Brijesh Kumar Chaubey (DIN: 10846247), as an Additional Executive Director of the Company
30-Dec-24	Company incorporated a subsidiary company namely "Grande Etoile Pharmaceuticals Limited"
08-Jan-25	Fund raise of Rs. 3 crores by way of creating, issuing and allotting up to 4,65,910 Convertible Warrants, at a price of ₹ 64.39/- per warrant, aggregating upto ₹
13-Mar-25	Approval of Preferential Issuance of upto 20,00,000 (Twenty Lakhs Only) equity shares to the person belonging to Non-Promoter, Public Category
13-Mar-25	issuance of 11,85,715 fully convertible warrants ("warrants") to the persons belonging to "promoter" and "non-promoter (public category)" category on preferential
13-Mar-25	Allotment of 4,65,910 fully Convertible Warrants to Mr. Bal Kishan Gupta, person belonging to "Promoter category"
13-Mar-25	approval for conversion of loan into 7,14,285 equity shares of the company on preferential basis to the persons belonging to promoter category
13-Mar-25	Appointment of Mr. Pankaj Tiwari (din: 11565750) as an Executive Director of the company
14-Nov-25	Submission of Certificate issued by the Statutory Auditors in respect of
27-Feb-26	To consider and approve variation in the objects of
27-Feb-26	Approval for the payment of remuneration to directors exceeding the overall managerial remuneration limit as per the provisions of Section197 of the companies act,
27-Feb-26	Re- appointment of Mr. Ashutosh Gupta (DIN:00039995) as Whole Time Director of the Company
17-Mar-26	approval for increase of authorised share capital of the company and consequent alteration of capital clause of memorandum of association of the company.
27-Mar-26	Re-appointment of Internal Auditor and Secretarial Auditor
09-Apr-26	Significant movement in price has been observed in Medicamen Organics Limited. The Exchange, in order to ensure that investors have latest relevant information
16-Apr-26	Medicamen Organics Limited has informed the Exchange about Change in Company Secretary/Compliance Officer
29-May-26	Medicamen Organics Limited has submitted to the Exchange, the audited financial results (Standalone and Consolidated) for the half-year and financial year ended
29-May-26	Medicamen Organics Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
21-Jul-26	Medicamen Organics Limited has informed the Exchange regarding Cessation of Mr Brijesh Kumar Chaubey as Executive Director of the company w.e.f. July 20,
21-Jul-26	Medicamen Organics Limited has informed the Exchange about Resignation of Director/KMP/SMP
31-Aug-26	Medicamen Organics Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026 along with the Annual
26-Sep-26	Medicamen Organics Limited has informed the Exchange regarding Change in Auditors of the company